Bone Marrow, Genetic Findings Distinguish IgM Myeloma From Waldenström Macroglobulinemia

Impact Journals LLC

"Accurate differentiation between IgM MM and WM is essential, as treatment and prognosis differ substantially."

BUFFALO, NY — November 19, 2026 — A new case report was published in Volume 13 of Oncoscience on October 19, 2026, titled " Clinical parallels and key distinctions: A diagnostic case of waldenström macroglobulinemia versus igm multiple myeloma ."

The report describes a rare case of immunoglobulin M (IgM) multiple myeloma that initially resembled Waldenström macroglobulinemia, another blood cancer with similar clinical features. The case highlights how bone marrow findings and genetic testing can help distinguish these conditions, which require different treatment approaches.

The case report's first and corresponding author is Aarish Lalani from the Ascension Saint Agnes Hospital in Baltimore, Maryland .

IgM multiple myeloma is an uncommon form of multiple myeloma, accounting for approximately 0.5% of cases. Like Waldenström macroglobulinemia, it involves abnormal production of IgM antibodies, making the two diseases difficult to distinguish through blood tests alone.

Although both conditions can cause elevated IgM levels and increased blood viscosity, they differ in their underlying cellular characteristics, treatment strategies and prognosis. IgM multiple myeloma primarily affects plasma cells, while Waldenström macroglobulinemia is a form of lymphoplasmacytic lymphoma.

The report describes a 67-year-old man who experienced persistent headaches, nausea and shortness of breath. Laboratory tests revealed markedly elevated IgM levels, increased blood viscosity and an abnormal monoclonal protein known as an M-spike.

However, the patient lacked several typical features of multiple myeloma, including anemia, elevated calcium levels, kidney dysfunction and destructive bone lesions. These findings made the diagnosis particularly challenging because some of the laboratory abnormalities also occur in Waldenström macroglobulinemia.

Further investigation revealed that 40–50% of the patient's bone marrow cells were plasma cells. Genetic testing also identified the t(11;14) chromosomal translocation, which is frequently associated with IgM multiple myeloma but rarely observed in Waldenström macroglobulinemia.

Together with the absence of lymphoid aggregates in the bone marrow, these findings led the medical team to diagnose IgM multiple myeloma despite the unusual presentation.

"Moreover, organomegaly and hyperviscosity are also not unique to WM."

The patient received eight cycles of chemotherapy with cyclophosphamide, bortezomib and dexamethasone, followed by an autologous stem cell transplant and lenalidomide maintenance therapy.

Treatment resulted in a substantial reduction in the abnormal monoclonal protein. Follow-up testing showed no detectable M-spike, and bone marrow biopsies performed one and two years after transplantation found no evidence of myeloma. The authors also reported continued remission without recurrence after maintenance therapy was discontinued.

The case demonstrates why the absence of classic multiple myeloma features does not necessarily rule out the disease. It also highlights the importance of combining laboratory testing, bone marrow examination and molecular analysis rather than relying on individual clinical findings.

However, this report describes a single patient, and its findings cannot establish how frequently similar diagnostic presentations occur or predict treatment outcomes in other patients.

Overall, the case emphasizes the importance of accurately distinguishing IgM multiple myeloma from Waldenström macroglobulinemia. A comprehensive diagnostic approach may help clinicians identify rare or atypical cases and select treatment strategies appropriate to the underlying disease.

DOI: https://doi.org/10.18632/oncoscience.679

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.